Peptide Initiative

Peptides · Peptide comparison

Cerebrolysin vs Dihexa

Porcine brain-derived neuropeptide preparation containing bioactive peptide fragments of neurotrophic factors, used clinically in over 40 countries for stroke recovery, traumatic brain injury, and cognitive impairment

Angiotensin IV-derived oligopeptide that potentiates hepatocyte growth factor to drive synaptogenesis and cognitive enhancement with extraordinary potency

  • Cognitive
  • Cognitive

At a glance

Quick comparison

Dose rangeCerebrolysin20–30 mLDihexa8–20 mg
FrequencyCerebrolysinOnce dailyDihexaOnce daily
AdministrationCerebrolysinIntravenous (IV) injection or infusionDihexaOral (capsule/tablet)
Cycle lengthCerebrolysin8-12 weeksDihexa4-6 weeks
Onset speedCerebrolysinModerate (1-2 weeks)DihexaModerate (1-2 weeks)
Evidence levelCerebrolysinModerate human trials (Phase 1-2)DihexaPreclinical only — animal and cell-culture studies; no human trials

Efficacy

Benefit ratings

Stroke Recovery

Cerebrolysin78%
DihexaNo recorded rating

Alzheimer's Support

Cerebrolysin72%
DihexaNo recorded rating

Brain Injury Healing

Cerebrolysin65%
DihexaNo recorded rating

Cognitive

CerebrolysinNo recorded rating
Dihexa95%

Healing & Recovery

CerebrolysinNo recorded rating
Dihexa60%

Anti-Aging

CerebrolysinNo recorded rating
Dihexa55%

Technical data

Compound specifications

Cerebrolysin

Molecular formula
Complex mixture — no single molecular formula (contains multiple peptide fragments and free amino acids derived from porcine brain proteins)
Molecular weight
Bioactive peptide components are all below 10 kDa (10,000 Da); the preparation contains a spectrum of peptide sizes
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
~85-100% (intramuscular injection)
CAS number
Not assigned (biological mixture)

Dihexa

Molecular formula
C27H44N4O5
Molecular weight
504.7 g/mol
Half-life
~12 days (following IV administration in rats)
Bioavailability
Orally active and blood-brain barrier permeable — specific oral bioavailability percentage not published
CAS number
1401708-83-5

Protocols

Dosing compared

Cerebrolysin

Intravenous

  • 10 mLOnce daily · 10-20 day course, repeated every 3-6 monthsA gentle starting dose given as a slow IV infusion (often diluted in saline). Used in dementia and recovery programs. [6][7]
  • 20-30 mLOnce daily · 10-21 day course, repeated in cyclesThe common clinical dose. Trials in vascular dementia used 20 mL daily, and stroke trials used 30 mL daily (diluted to about 100 mL saline) infused over ~30 minutes. [6][7]
  • 30-50 mLOnce daily · 10-21 days for stroke or severe brain injuryThe higher end used for acute stroke and severe traumatic brain injury, given as a diluted IV infusion under medical supervision. [7]

Intramuscular

  • 5-10 mLOnce daily · Up to 10-20 days per courseFor smaller doses, Cerebrolysin can be given as an intramuscular injection (no more than ~5 mL per injection site). Often used for milder cases or maintenance between IV cycles. [7]

Dihexa

Oral

  • 5–8 mgOnce daily · 2–4 weeksLower starting amount reported in practice. Dihexa has no human clinical trials, so all amounts come from animal research and community use [2][4].
  • 8–20 mgOnce daily · 4–6 weeksCommonly reported daily range in practice for cognitive support [2][4].
  • 20–45 mgOnce daily · 4–6 weeks, then reassessUpper end of amounts reported in practice. No long-term human safety data exists, so this should be approached with caution [2][4].

Sublingual

  • 5–15 mgOnce daily · 4–6 weeksHeld under the tongue as an alternative to swallowing; amounts reported in practice are similar to oral use [4].

Topical

  • 5–15 mg in DMSO carrierOnce daily · 4–6 weeksApplied to the skin in a DMSO solution to help absorption; used in practice as a non-oral option [4].

Applications

Best suited for

Cerebrolysin

Post-stroke neurorecovery and rehabilitation support
Cerebrolysin is particularly well-suited for individuals focused on post-stroke neurorecovery and rehabilitation support. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [2][13].
Cognitive support in Alzheimer's disease and vascular dementia
Cerebrolysin is particularly well-suited for individuals focused on cognitive support in alzheimer's disease and vascular dementia. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1][6].
Traumatic brain injury recovery and neuroprotection
Cerebrolysin is particularly well-suited for individuals focused on traumatic brain injury recovery and neuroprotection. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [14].
Age-related cognitive decline and mild cognitive impairment
Cerebrolysin is particularly well-suited for individuals focused on age-related cognitive decline and mild cognitive impairment. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [1].

Dihexa

Age-Related Cognitive Decline
Dihexa directly addresses the synaptic loss that underlies age-related cognitive decline by building new functional synaptic connections in the hippocampus. Animal studies demonstrate restored spatial learning in aged rats, [6] making it a compelling candidate for combating memory loss associated with aging.
Neuroplasticity Enhancement
Unlike nootropics that work through neurotransmitter modulation, dihexa drives physical neuroplasticity — the formation of new dendritic spines and synapses. [6] This makes it ideal for individuals looking to enhance their brain's capacity for learning and adaptation at a structural level.
Neurodegenerative Disease Research
Preclinical evidence in APP/PS1 Alzheimer's mice and scopolamine-induced amnesia models [4][6] positions dihexa as a leading research compound for neurodegenerative disease. It is patented for potential use in Alzheimer's and Parkinson's diseases, with ongoing interest from the research community.
Advanced Nootropic Stacking
Dihexa's unique mechanism (HGF/c-Met potentiation) is complementary to most other nootropic mechanisms, making it an excellent addition to advanced cognitive enhancement protocols when combined with choline donors, racetams, or adaptogens.

Safety profile

Side effects

Cerebrolysin

Common

  • Injection site reactions
  • Headache
  • Dizziness and vertigo
  • Nausea and gastrointestinal discomfort
  • Agitation or restlessness
  • Fever

Uncommon

  • Allergic reaction

Serious

  • Severe hypersensitivity reaction

Dihexa

Common

  • Headache
  • Vivid dreams or altered sleep patterns
  • Emotional sensitivity
  • Mild fatigue during adjustment

Uncommon

  • Gastrointestinal discomfort

Serious

  • Theoretical oncogenic risk from c-Met activation

Research status

Safety & evidence

Cerebrolysin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Cerebrolysin is an FDA-unregulated neuroprotective agent consisting of porcine brain-derived peptides and amino acids that has been used primarily in Eastern Europe and Asia. [8][12] Safety data is limited to observational clinical use and small open-label trials rather than rigorous randomized controlled trials with formal safety monitoring. As a complex mixture of undefined peptide fragments from animal sources, batch consistency and sterility cannot be guaranteed without pharmaceutical manufacturing standards. Potential allergic reactions to porcine proteins and transmissible spongiform encephalopathy (TSE) risks from animal-derived components have not been adequately ruled out.

Contraindications

  • Known hypersensitivity to Cerebrolysin or porcine-derived products
  • Severe renal impairment or renal failure
  • Status epilepticus or uncontrolled epilepsy
  • Pregnancy and breastfeeding — insufficient safety data

Dihexa

Evidence level
Preclinical only — animal and cell-culture studies; no human trials
FDA status
Research compound
Safety overview
Dihexa has demonstrated a favorable safety profile in published animal studies, with no reported tumorigenic effects or organ toxicity at cognitive-enhancing doses. However, the compound has not undergone formal human clinical trials, and long-term safety data does not exist. [7] The primary theoretical safety concern is sustained activation of the HGF/c-Met proto-oncogenic pathway, which could theoretically promote tumor initiation or growth. [7] The extremely long half-life (~12 days) [6][7] raises additional concerns about compound accumulation with chronic daily dosing. Anecdotal reports from the nootropics community generally describe good tolerability at doses of 5-20 mg daily, with headaches and vivid dreams as the most commonly reported effects.

Contraindications

  • Known or suspected malignancy — c-Met/HGF pathway activation may promote tumor growth
  • Pregnancy and breastfeeding — no safety data available
  • History of cancer, particularly HGF/c-Met-driven tumors (hepatocellular, gastric, lung)
  • Severe hepatic impairment

Decision guide

Which is right for you?

Cerebrolysin

Choose Cerebrolysin if…

  • Post-stroke neurorecovery and rehabilitation support
  • Cognitive support in Alzheimer's disease and vascular dementia
  • Traumatic brain injury recovery and neuroprotection
  • Age-related cognitive decline and mild cognitive impairment

Dihexa

Choose Dihexa if…

  • Cognitive enhancement and memory consolidation in age-related decline
  • Supporting neuroplasticity and new synaptic connection formation
  • Research into neurodegenerative disease therapeutics (Alzheimer's, Parkinson's)
  • Nootropic stacking for individuals seeking enhanced learning capacity